Randomized Controlled Trial of the Electrocardiographic Effects of Four Antimalarials for Pregnant Women with Uncomplicated Malaria on the Thailand-Myanmar Border

Makoto Saito,a,b,c Widi Yotyingaphiram,a Zillah Cargill,a,d Mary Ellen Gilder,a,e Aung Myat Min,a,b Aung Pyae Phyo,a,b Thi Dar San,a Hilda Poe,a Cindy Chu,a,b Nicholas J. White,a,f François Nosten,a,b Rose McGready,a,b

aShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand
bCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
cDivision of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
dMaidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Kent, United Kingdom
eDepartment of Family Medicine, Chiang Mai University, Chiang Mai, Thailand
fMahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

ABSTRACT Quinoline antimalarials cause drug-induced electrocardiographic QT prolongation, a potential risk factor for torsade de pointes. The effects of currently used antimalarials on the electrocardiogram (ECG) were assessed in pregnant women with malaria. Pregnant women with microscopy-confirmed parasitemia of any malaria species were enrolled in an open-label randomized controlled trial on the Thailand-Myanmar border from 2010 to 2016. Patients were randomized to the standard regimen of dihydroartemisinin-piperaquine (DP) or artesunate-mefloquine (ASMQ) or an extended regimen of artemether-lumefantrine (AL). Recurrent Plasmodium vivax infections were treated with chloroquine. Standard 12-lead electrocardiograms were assessed on day 0, 4 to 6 h following the last dose, and day 7. QT was corrected for the heart rate by a linear mixed-effects model-derived population-based correction formula (QTcP = QT/RR0.381). A total of 86 AL, 82 ASMQ, 88 DP, and 21 chloroquine-treated episodes were included. No patients had an uncorrected QT interval nor QTcP of ≥480 ms at any time. QTcP corresponding to peak drug concentration was longer in the DP group (adjusted predicted mean difference, 17.84 ms; 95% confidence interval [CI], 11.58 to 24.10; P < 0.001) and chloroquine group (18.31 ms; 95% CI, 8.78 to 27.84; P < 0.001) than in the AL+ group, but not different in the ASMQ group (2.45 ms; 95% CI, −4.20 to 9.10; P = 0.47) by the multivariable linear mixed-effects model. There was no difference between DP and chloroquine (P = 0.91). QTc prolongation resulted mainly from widening of the JT interval. In pregnant women, none of the antimalarial drug treatments exceeded conventional thresholds for an increased risk of torsade de pointes.

KEYWORDS QT prolongation, cardiotoxicity, chloroquine, JT interval, lumefantrine, malaria, mefloquine, piperaquine, pregnancy, safety

Quinoline and structurally related antimalarials have pharmacological activity on the cardiovascular system. Quinidine, the dextrorotatory diastereomer of quinine, has been used mainly as a class 1a antiarrhythmic rather than as an antimalarial, despite its greater antimalarial activity than quinine (1, 2). Halofantrine was withdrawn because, after registration, it was found to cause marked prolongation of QT interval in therapeutic doses (3), and it was associated with sudden cardiac deaths (1, 3, 4). Although drug-induced QT prolongation has been reported for other antimalarials, namely, chloroquine, amodiaquine, mefloquine, lumefantrine, and piperaquine (1,
previous studies conducted in malaria patients and also in healthy adult volunteers have found that the cardiovascular safety profile of currently used antimalarials is generally reassuring.

Pregnant women are a subgroup for whom drug toxicity may differ from other individuals because of the physiological and pharmacokinetic/pharmacodynamic differences resulting from pregnancy itself (9–11). The QT-prolonging effect of medications is consistently higher in women than in men (1, 7, 12), while changes in sex hormones during pregnancy can shorten the QT interval (13). There have been few detailed electrocardiographic studies of antimalarials in pregnancy. Furthermore, more than half of the pregnant women studied in reports of electrocardiographic effects were healthy volunteers taking antimalarials as prevention, rather than women with malaria parasitemia taking treatment (14–27).

Malaria infection itself affects the QT interval, and defervescence contributes to a substantial reduction in heart rate and lengthening of the QT interval between the acute admission and 3 days later when drug levels are at their highest (1). Therefore, in patients with malaria parasitemia, differences in QT intervals before and after drug administration are not attributable only to the effect of drugs. Comparing the QT interval changes between malaria patients assigned to different treatment regimens allows assessment of the impact of different drugs without confounding from the resolving malaria infection itself. QT prolongation can be caused by delaying ventricular depolarization (class 1c effect) or repolarization (class 3 effect) (1). Differentiation, by dividing QT into the QRS and JT intervals, is important, as class 3 antiarrhythmics can cause torsades de pointes, and the risk has been reported to be higher in women (28). Few studies on antimalarials have differentiated these two effects.

We compared QT and JT intervals before and after four different antimalarials (extended regimen of artemether-lumefantrine [AL+], artesunate-mefloquine [ASMQ], dihydroartemisinin-piperaquine [DP], and chloroquine [CHQ]) in pregnant women who were enrolled in a randomized controlled trial (RCT) of antimalarial treatments for uncomplicated malaria in pregnancy on the Thailand-Myanmar border.

**RESULTS**

**Baseline characteristics.** Among 511 pregnant women enrolled in the RCT, 256 pregnant women (86 AL+, 82 ASMQ, and 88 DP) had electrocardiogram (ECG) assessments (Fig. S1 in the supplemental material). During the follow-up, there were 71 recurrences of *Plasmodium vivax* before delivery that were treated with CHQ, and 21 of them were assessed by ECG. Twenty patients had two episodes where ECGs were assessed; the median interval between two episodes was 67 (range, 27 to 133) days.

From 279 malaria episodes in 259 pregnant women, 754 ECG records were performed: at baseline before drug administration (day 0; \( n = 273 \)), at 4 to 6 h following the last dose (defined as day peak; \( n = 256 \)), and on day 7 or after (day 7; \( n = 225 \)). The recording speed of the ECG was 50 mm/s in 98.7% (744/754) of the records. Some records were excluded from the analyses, including ECG assessed after drug administration on day 0 (\( n = 2 \)); \(<6 \) leads assessed on day 0 (\( n = 2 \)), on day peak (\( n = 2 \)), or on day 7 (\( n = 3 \)); and poor quality on day 0 (\( n = 1 \)). Appropriate ECGs on all 3 days were available in 205 episodes.

The mean age of the pregnant women with uncomplicated malaria was 25.6 years (standard deviation [SD], 6.9; range, 18 to 45), and the mean gravidity was 2.9 (SD, 2.0; maximum, 10). The mean estimated gestational age (EGA) on day 0 was 26.0 weeks (SD, 8.3; range, 7.0 to 40.1). There were 79 *Plasmodium falciparum* monoinfections, 194 *P. vivax* monoinfections, 5 coinfections of *P. falciparum* and *P. vivax*, and 1 *Plasmodium malariae* monoinfection. Only 30.2% (84/278) were febrile (body temperature >37.5°C) at presentation.

There were no apparent differences in baseline characteristics among the three randomized treatment groups (Table 1). CHQ was used exclusively for mildly symptomatic recurrences of *P. vivax* monoinfection. There were no apparent differences between those who were assessed by ECG and those who were not (Table S1).
### TABLE 1 Baseline characteristics on day 0 of pregnant women who were assessed by ECG

| Characteristic                          | All participants | AL+<sup>a</sup> | ASMQ | DP | CHQ |
|-----------------------------------------|------------------|-----------------|------|----|-----|
| **No. of women**                        |                  |                 |      |    |     |
| **Age (yrs)**                           | 259<sup>b</sup>  | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 25.6 (6.9)       | 25.1 (7.1)      | 25.8 (6.6) | 25.5 (6.9) | 25.7 (7.6) |
| **Gravidity**                           | 259<sup>b</sup>  | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 2.9 (2.0)        | 2.9 (2.2)       | 3.0 (2.1) | 2.7 (1.8) | 3.1 (2.0) |
| **Height (cm)**                         | 259<sup>b</sup>  | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 151.0 (5.6)      | 151.0 (6.1)     | 151.4 (4.9) | 150.9 (5.9) | 150.8 (5.2) |
| **Smoking**                             | 259<sup>b</sup>  | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 20.8% (5.4)      | 23.3% (20)      | 18.3% (15) | 19.3% (17) | 28.6% (6)  |
| **Gestational age (wks)**               | 279              | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 26.0 (8.3)       | 25.7 (8.6)      | 26.5 (8.9) | 24.6 (7.8) | 29.8 (5.3) |
| **Weight (kg)**                         | 276              | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 52.3 (8.0)       | 51.2 (7.8)      | 53.1 (7.6) | 51.8 (8.3) | 55.5 (8.0) |
| **Fever (>37.5°C)**                     | 278              | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 30.2% (84)       | 33.7% (29)      | 34.1% (28) | 27.3% (24) | 14.3% (3)  |
| **Heart rate (per min)**                | 273              | 84              | 80   | 88 | 19  |
| **Mean (SD) or %**                       | 93.6 (16.2)      | 96.2 (17.2)     | 95.6 (16.0) | 91.0 (15.7) | 86.8 (12.6) |
| **Hematocrit (%)**                      | 279              | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 32.4 (3.7)       | 32.3 (3.3)      | 32.8 (4.3) | 32.3 (3.8) | 31.9 (2.7) |
| **Malaria species infection type**      |                  |                 |      |    |     |
| *P. falciparum* monoinfection**          | 279              | 82              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 28.3% (79)       | 30.2% (26)      | 35.4% (29) | 25.0% (22) | 0.0% (0)   |
| *P. vivax* monoinfection**              | 279              | 82              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 69.5% (194)      | 68.6% (59)      | 62.2% (51) | 71.6% (63) | 100.0% (21) |
| *P. falciparum* plus *P. vivax*         | 279              | 82              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 1.8% (5)         | 1.2% (1)        | 2.4% (2) | 2.3% (2) | 0.0% (0)   |
| *Plasmodium malariae* monoinfection     | 279              | 82              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 0.4% (1)         | 0.0% (0)        | 0.0% (0) | 1.1% (1) | 0.0% (0)   |
| **Asexual parasite load/μl**            | 279              | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 10,262.9 (21,418.2) | 10,304.4 (19,886.1) | 13,090.7 (25,924.4) | 9,621.2 (20,502.7) | 2,400.8 (6,403.9) |
| **Presence of gametocyte**              | 279              | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 48.4% (135)      | 47.7% (41)      | 40.2% (33) | 52.3% (46) | 66.7% (14) |
| **Anorexia**                            | 279              | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 38.0% (106)      | 38.4% (33)      | 40.2% (33) | 37.5% (33) | 23.8% (5)  |
| **Nausea**                              | 279              | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 31.5% (88)       | 36.0% (31)      | 37.8% (31) | 29.5% (26) | 0.0% (0)   |
| **Vomiting**                            | 279              | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 16.1% (45)       | 12.8% (11)      | 24.4% (20) | 14.8% (13) | 0.0% (0)  |
| **Dizziness**                           | 279              | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 63.1% (176)      | 64.0% (55)      | 61.0% (50) | 68.2% (60) | 47.6% (10) |
| **Diarrhea**                            | 279              | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 2.2% (6)         | 3.5% (3)        | 0.0% (0) | 3.4% (3) | 0.0% (0)   |
| **Palpitation**                         | 279              | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 31.5% (88)       | 33.7% (29)      | 30.5% (25) | 37.5% (33) | 0.0% (0)   |
| **Fatigue**                             | 279              | 86              | 82   | 88 | 21  |
| **Mean (SD) or %**                       | 53.8% (150)      | 50.0% (43)      | 56.1% (46) | 55.7% (49) | 47.6% (10) |

<sup>a</sup>AL+, extended artemether-lumefantrine; ASMQ, artesunate-mefloquine; CHQ, chloroquine; DP, dihydroartemisinin-piperaquine.<br>
<sup>b</sup>Only the first episode was included.
Heart rate, QTu, QTcF, and QTcB. The mean heart rate on day 0 was 93.4 beats per minute (SD, 16.2), 78.6 (SD, 11.8) on day peak, and 86.2 (SD, 12.9) on day 7. Bradycardia (heart rate ≤ 60 beats/min) on day peak was observed in 13 patients, including 9.8% (8/82) of AL, 2.6% (2/78) of ASMQ, 2.5% (2/79) of DP, and 5.9% (1/17) of CHQ. Of the symptoms that might be associated with bradycardia, only 2 of the 13 patients complained of dizziness (one each in DP and ASMQ). None of them had vomited. There were no maternal deaths nor cases with life-threatening arrhythmias. On day 0, the mean uncorrected QT (QTu) was 334.3 ms (SD, 27.4), QT corrected by the Fridericia method (QTcF) was 384.8 ms (SD, 20.4), and by the Bazett method (QTcB) was 413.4 ms (SD 23.4) (Table S2). There were no apparent differences on day 0 among the treatment groups. No patients had QTu or QTcF longer than 480 ms at any time, but QTcB was longer than 480 ms in three women, with a maximum value of 493 ms.

Compared with the baseline, a QTcF increase of >30 ms was observed on day peak in 10.1% (8/79) of AL, 16.4% (12/73) of ASMQ, 37.5% (6/16) of CHQ, and 40.4% (31/77) of DP (Table 2). A QTcF increase of >60 ms was observed only in DP (5.2%, 4/77), with a maximum of 68 ms. Compared with the baseline, a QTcB increase of >30 ms was observed on day peak in 7.6% (6/79) of AL, 5.5% (4/73) of ASMQ, 25.0% (4/16) of CHQ, and 30.2% (24/77) of DP recipients (Table 2). A QTcB increase of >60 ms was observed in DP (2.6%, 2/77) and CHQ (6.3%, 1/16), with a maximum of 72 ms.

QTc by population-based correction. Using the day 0 data, the population-based heart rate correction formula obtained was QTcP = QTu/RR0.381. QTc by population-based correction (QTcP) was no longer associated with heart rate by linear regression analysis (coefficient, −0.016; 95% confidence interval [CI], −0.17 to 0.14; P = 0.84), while QTcF (coefficient, −0.20; 95% CI, −0.35 to −0.06; P = 0.007) and QTcB (coefficient, 0.49; 95% CI, 0.33 to 0.65; P < 0.001) were associated with heart rate on day 0 (Fig. S2). No association between QTcP and heart rate was also observed for day peak and day 7; thus, QTcP was used for further analyses.

Factors associated with QTcP. In the univariable analysis, QTcP on day peak was longer in DP (mean difference, 17.49 ms; 95% CI, 12.37 to 22.62; P < 0.001) and CHQ (13.62 ms; 95% CI, 5.41 to 21.82; P = 0.001) than AL, but no different in ASMQ (20.37 ms; 95% CI, −5.54 to 4.81; P = 0.89). On day 7, there was no difference among the treatment groups (P = 0.40).

In the multivariable analysis (Table 3), QTcP on day peak was longer in DP (adjusted mean difference, 17.84 ms; 95% CI, 11.58 to 24.10; P < 0.001) and CHQ (13.62 ms; 95% CI, 5.41 to 21.82; P = 0.001) than AL, but no different in ASMQ (−0.37 ms; 95% CI, −5.54 to 4.81; P = 0.89). On day 7, there was no difference among the treatment groups (P = 0.40). QTcP on day 7 was longer than day 0 in AL and ASMQ, but there was no difference from day 0 in DP and CHQ (Fig. 1); the adjusted mean difference from day 0 was 5.64 ms (95% CI, 0.76 to 10.52) in AL, 5.59 ms (95% CI, 0.90 to 10.27) in ASMQ, 0.53 ms (95% CI, −4.47 to 5.53) in DP, and 6.71 ms (95% CI, −0.64 to 14.05) in CHQ.

Variables associated with longer QTcP were age (adjusted mean difference, 0.53 ms/year; 95% CI, 0.24 to 0.81; P < 0.001), asexual parasite density (0.11 ms/1,000/μl; 95% CI, 0.02 to 0.19; P = 0.02), presence of gametocytemia (adjusted mean difference between those who had gametocytemia and those who did not, 13.53 ms; 95% CI, 3.17 to 23.90; P = 0.01), and diarrhea (23.16 ms; 95% CI, 8.18 to 38.14; P = 0.002). Increasing EGA was associated with shorter QTcP (−0.40 ms/week; 95% CI, −0.62 to −0.18; P < 0.001). As the time of day when ECG was assessed was a confounder for treatment effect, it was included in the final model. Although not statistically significant, QTcP was longer when the ECG was assessed between midnight and 06:00, consistent with diurnal change (Table 3).
Sensitivity analyses. In a sensitivity analysis excluding women who were given concomitant medications that could potentially influence QT interval (n = 14) or who received blood transfusions (n = 1), the conclusions were unchanged (Fig. S3).

To avoid overadjustment by assuming the same QTcP on day 0, a sensitivity analysis was conducted using a model that allowed a difference in the baseline QTcP on day 0 among different treatment groups. In this sensitivity analysis, the point estimates were very similar to the primary model (Fig. S3). Even in the model which allowed differences in the QTcP on day 0, there was no significant difference in the QTcP on day 0 among the treatment groups with or without adjusting for other covariates, which justifies our assumption of no difference in the primary model.

JT interval. The prolongation of QT interval on day peak from the baseline was mostly due to the prolongation of JT interval regardless of the correction methods (Fig. S4). No patients had bundle branch block (an abnormally wide QRS interval of >120 ms). The effect of different antimalarials on the JTc interval was similar to that on QTcP (Fig. S3). In the multivariable analysis, JTc on day peak was longer in DP (adjusted mean difference, 14.47 ms; 95% CI, 7.83 to 21.12; P < 0.001) and CHQ (15.24 ms; 95% CI, 5.14 to 25.33; P = 0.003) than AL, but not different in ASMQ (−0.53 ms; 95% CI, −7.58 to 6.53; P = 0.88).

DISCUSSION

This study in pregnant women with acute uncomplicated malaria shows that DP and CHQ prolong the electrocardiographic QT interval by a similar magnitude, consistent with observations in healthy Thai male and female (nonpregnant) adult volunteers (29, 30). DP and CHQ prolongation mainly reflect delayed ventricular repolarization as it resulted from prolongation of JT interval rather than the widening of QRS. This effect was larger than for AL+ or ASMQ-treated women.

We are not aware of any prior studies reporting ECG intervals for pregnant women receiving CHQ. No clinically relevant abnormalities have been reported in ECG studies of antimalarials in pregnant women on prevention, including mefloquine (n = 80) (14, 15) and DP (n = 492) (16–22), or treatment, including quinine (n = 152) (23), AL (n = 203) (23–25), artesunate-amodiaquine (n = 83) (26), and artesunate-atovaquone-proguanil (n = 22) (27). However, piperaquine, a bisquinoline, used in the form of DP and highly effective except in the Eastern Greater Mekong subregion, has been a focus of interest due to potential cardiotoxicity. This arose from one possibly drug-

**TABLE 2** Difference in QT intervals by various correction methods from the baseline

| Measurement (day peak − day 0) | Data for treatment group: | All | AL+a | ASMQ | DP | CHQ |
|--------------------------------|--------------------------|-----|------|------|----|-----|
|                               | Total                     | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
| QT uncorrected (ms) 245        | 34.5 (26.4)               | 32.0 (27.4) | 29.6 (27.0) | 41.4 (23.2) | 36.3 (23.9) |
| QT >30 ms 245                  | 64.5% (158)              | 62.0% (49) | 53.4% (39) | 76.6% (59) | 68.8% (11) |
| QT >60 ms 245                  | 19.6% (48)                | 12.7% (10) | 21.9% (16) | 24.7% (19) | 18.8% (3)  |
| ΔQTc Fridericia (ms) 245       | 15.84 (20.9)              | 9.76 (18.9) | 9.02 (19.9) | 26.6 (20.0) | 25.3 (14.5) |
| QTc Fridericia >30 ms 245      | 23.3% (57)                | 10.1% (8) | 16.4% (12) | 40.3% (31) | 37.5% (6)  |
| QTc Fridericia >60 ms 245      | 1.6% (4)                  | 0.0% (0) | 0.0% (0) | 5.2% (4) | 0.0% (0) |
| ΔQTc Bazett (ms) 245           | 4.58 (24.96)              | −3.54 (23.4) | −3.45 (23.0) | 17.6 (22.9) | 18.7 (18.7) |
| QTc Bazett >30 ms 245          | 15.5% (38)                | 7.6% (6) | 5.5% (4) | 31.2% (24) | 25.0% (4) |
| QTc Bazett >60 ms 245          | 1.2% (3)                  | 0.0% (0) | 0.0% (0) | 2.6% (2) | 6.3% (1)  |
| ΔQTcP (ms) 245                 | 12.7 (21.5)               | 6.11 (19.5) | 5.60 (20.2) | 24.1 (20.4) | 23.5 (15.0) |
| QTcP >30 ms 245                | 19.6% (48)                | 10.1% (8) | 8.2% (6) | 36.4% (28) | 37.5% (6)  |
| QTcP >60 ms 245                | 1.6% (4)                  | 0% (0) | 0% (0) | 5.2% (4) | 0% (0) |

*aAL+, extended artemether-lumefantrine; ASMQ, artesunate-mefloquine; CHQ, chloroquine; Δ, difference; DP, dihydroartemisinin-piperaquine; QTc Fridericia, QT interval corrected by Fridericia method; QTc Bazett, QT interval corrected by Bazett method; QTcP, QT interval corrected by population-based correction (QT/RR0.381).
related sudden death after DP (nonpregnant) among several hundred thousand exposed individuals, a death rate that was not higher than the background population risk (31).

Malaria infection has been proposed as a cause of QTc shortening (1) due to increased sympathetic tone, and this can be independent of heart rate (32). Higher body temperature was also shown to be associated with a shorter QT interval.

### TABLE 3 Factors associated with QTcP by multilevel univariable and multivariable linear regressiona

| Variable                                      | Univariable linear regression results | Multivariable linear regression results |
|-----------------------------------------------|----------------------------------------|----------------------------------------|
|                                               | No. of patients | Mean difference (95% CI) | P value | No. of patients | Mean difference (95% CI) | P value |
| Time and treatment type (interaction)         |              |                          |         |              |                          |         |
| Day peak                                      |              |                          |         |              |                          |         |
| AL+                                           | 70           | Reference                |         | 70           | Reference                |         |
| ASMQ                                          | 74           | −0.37 (−5.54 to 4.81)   | 0.89    | 76           | 2.45 (−4.20 to 9.10)    | 0.47    |
| DP                                            | 79           | 17.49 (12.37 to 22.62)  | <0.001  | 79           | 17.84 (11.58 to 24.10)  | <0.001  |
| CHQ                                           | 15           | 13.62 (5.41 to 21.82)   | 0.001   | 14           | 18.31 (8.78 to 27.84)   | <0.001  |
| Day 7                                         |              |                          |         |              |                          |         |
| AL+                                           | 64           | Reference                |         | 64           | Reference                |         |
| ASMQ                                          | 66           | −0.05 (−5.54 to 5.44)   | 0.99    | 67           | −0.05 (−5.59 to 5.48)   | 0.99    |
| DP                                            | 62           | −4.06 (−9.53 to 1.42)   | 0.15    | 62           | −5.11 (−10.70 to −0.48) | 0.07    |
| CHQ                                           | 20           | −0.13 (−7.72 to 7.45)   | 0.97    | 20           | 1.07 (−6.64 to 8.77)    | 0.79    |
| Day (for AL+)                                 |              |                          |         |              |                          |         |
| 0                                             | 83           | Reference                |         | 83           | Reference                |         |
| Peak                                          | 64           | 6.28 (2.49 to 10.06)     | 0.001   | 64           | 6.78 (1.36 to 12.19)    | 0.01    |
| 7                                             | 70           | 3.57 (−0.44 to 7.57)     | 0.081   | 70           | 5.64 (0.76 to 10.52)    | 0.02    |
| Age                                           | 748          | 0.53 (0.25 to 0.81)      | <0.001  | 720          | 0.53 (0.24 to 0.81)     | <0.001  |
| Gravidity                                     | 748          | 1.76 (0.80 to 2.73)      | <0.001  |               |                         |         |
| Height                                        | 748          | 0.06 (−0.29 to 0.42)     | 0.72    |               |                         |         |
| Smoking                                       | 154/748      | 0.78 (−4.21 to 5.77)     | 0.76    |               |                         |         |
| EGA                                           | 748          | −0.43 (−0.65 to −0.21)   | <0.001  | 720          | −0.40 (−0.62 to −0.18)  | <0.001  |
| Weight                                        | 745          | 0.004 (−0.25 to 0.26)    | 0.97    |               |                         |         |
| Fever (>37.5°C)                               | 80/683       | 2.57 (−1.68 to 6.82)     | 0.24    |               |                         |         |
| Body temperature                              | 679          | −1.47 (−4.07 to 1.13)    | 0.27    |               |                         |         |
| Heart rate                                    | 748          | 0.07 (−0.03 to 0.16)     | 0.18    |               |                         |         |
| Hematocrit                                    | 584          | −0.33 (−0.78 to 0.12)    | 0.15    |               |                         |         |
| Malaria species infection                     |              |                          |         |              |                          |         |
| Negative                                      | 438          | Reference                |         |               |                         |         |
| P. falciparum monoinfection                   | 110          | 0.09 (−5.58 to 5.77)     | 0.97    |               |                         |         |
| P. vivax monoinfection                        | 192          | −1.35 (−7.35 to 4.66)    | 0.66    |               |                         |         |
| P. falciparum plus P. vivax                   | 5            | −3.71 (−18.42 to 11.00)  | 0.62    |               |                         |         |
| P. malariae monoinfection                     | 1            | 0.47 (−30.77 to 31.70)   | 0.98    |               |                         |         |
| Asexual parasitemia                           | 746          | 0.12 (0.03 to 0.21)      | 0.007   | 720          | 0.11 (0.02 to 0.19)     | 0.02    |
| Gametocytamia                                 | 135/747      | 135/720                  |         |               |                         |         |
| Between women                                 |              |                          |         |              |                          |         |
| Within the same woman                         | 16.63 (6.17 to 27.10) | 0.002 | 13.53 (3.17 to 23.90) | 0.01 |
| Within the same woman                         | −0.79 (−4.77 to 3.19) | 0.70 | −1.08 (−5.06 to 2.91) | 0.60 |
| Anorexia                                      | 135/721      | 135/720                  |         |               |                         |         |
| Between women                                 |              |                          |         |              |                          |         |
| Within the same woman                         | 8.80 (1.69 to 15.92) | 0.02 | 13.53 (3.17 to 23.90) | 0.01 |
| Within the same woman                         | −2.10 (−6.27 to 2.08) | 0.33 | −1.08 (−5.06 to 2.91) | 0.60 |
| Vomiting                                      | 55/723       | 5.23 (0.41 to 10.06)     | 0.03    |               |                         |         |
| Diarrhea                                      | 5/722        | 27.49 (12.25 to 42.73)   | <0.001  | 5/720         | 23.16 (8.18 to 38.14)   | 0.002  |
| Time ECG assessed                             |              |                          |         |              |                          |         |
| 0:00 to 5:59                                  | 39           | 2.31 (−4.28 to 8.91)     | 0.49    | 36           | 3.13 (−3.68 to 9.93)    | 0.37    |
| 6:00 to 11:59                                 | 313          | −1.69 (−4.78 to 1.40)    | 0.29    | 296           | −0.32 (−3.47 to 2.83)   | 0.84    |
| 12:00 to 17:59                                | 309          | Reference                |         | 302           | Reference                |         |
| 18:00 to 23:59                                | 87           | −2.07 (−6.74 to 2.60)    | 0.39    | 86            | −2.85 (−7.49 to 1.79)   | 0.23    |

aAL, extended artether-lumefantrine; ASMQ, artesunate-mefloquine; CHQ, chloroquine; CI, confidence interval; DP, dihydroartemisinin-piperaquine; ECG, electrocardiogram; EGA, estimated gestational age. P value by Wald test. Random-slope models were used for accounting for within-person correlation. Day and interaction between day and treatment were included in the models as forced variables. Multivariable model includes all the variables listed in the column.
A 2.80 ms/1°C increase; 95% credible interval, 2.17 to 2.42 ms) in malaria patients before treatment in a recent meta-analysis (7). The results presented here were generally similar in direction and magnitude with previously reported effects in nonpregnant females. The QTcP on day 0 was slightly shorter than that on day 7 for all treatment groups, and QTcP of pregnant women with higher body temperature was shorter (−1.47 ms/1°C increase; 95% CI, −4.07 to 1.13), though some of these trends did not reach statistical significance. In contrast, QTc lengthening has also been associated with intensity of malaria infection: higher parasitemia has been reported to be associated with a longer QTcB in children in one previous study (33). In the data presented here, there was a strong association between both an increasing asexual parasite density and presence of gametocytes and prolongation of the QTcP. Differences in the effect of infection on QTc by species has been reported (7) but was not found in this study.

Additional variables associated with QTc that were consistent with previous studies included prolongation of QTc with advancing age and diarrhea (34, 35) and diurnal change in QTc (36–38). Higher gestational age was associated with a shorter QTc. Similarly, one previous DP preventative treatment study (largely asymptomatic women) reported that QTc prolongation decreased in later pregnancy (21). This finding may be due to the level of progesterone (or the ratio of progesterone to estradiol), which increases toward the end of pregnancy (13, 39), or possibly the lower blood concentration (i.e., higher volume of distribution) of the partner drug later in the pregnancy (40).

QTcF was associated with heart rate in our study population. QTcB is known to overadjust QT in people with higher heart rate, which was observed in our cohort. As patients with malaria are more likely to have increased heart rate due to fever, QTcP should be a better measurement to compare drug effects in individuals where heart rate is expected to change over the treatment course.

There are some limitations to this study. Randomization was only done for AL+, ASMQ, and DP. CHQ was used for P. vivax recurrence, so some baseline characteristics, such as parasitemia load and symptoms, were not comparable with the other three drugs where allocation was randomized. The sensitivity analysis allowing difference on day 0, however, reached the same conclusion. Importantly, there was no difference in baseline QTc interval among these four drugs. Therefore, our conclusion on the drug effect, which was measured as the difference in QTcP from baseline, will not change.

In conclusion, our results indicate that the impact of DP on QTc prolongation in pregnant women with malaria was similar to that of CHQ. Although both DP and CHQ

![Graph showing difference in adjusted QTc by population-based correction method from baseline over time by treatment. 95% confidence intervals are shown as whiskers. AL+, extended artemether-lumefantrine; ASMQ, artesunate-mefloquine; CHQ, chloroquine; DP, dihydroartemisinin-piperaquine.](aac.asm.org)
were associated with a similarly longer QTc interval on day peak than AL+ or ASMQ, the recorded longest QTc interval did not exceed the known threshold for increased risk for fatal arrhythmia. The drug effect on QTc did not remain on day 7. This study thus demonstrated a safe cardiotoxic profile of the currently used antimalarials (namely, AL+, ASMQ, DP, and CHQ) for treating uncomplicated malaria in pregnancy.

MATERIALS AND METHODS

Study site and eligibility criteria. This study was a part of a randomized controlled trial (RCT) in pregnancy conducted from 2010 to 2016 on the Thailand-Myanmar border, details of which are described elsewhere (ClinicalTrials.gov identifier NCT01054248). Briefly, pregnant women were screened for malaria parasites by blood smear at the first antenatal consultation and then every 2 weeks, and women with positive parasitemia were assessed for eligibility. Inclusion criteria were age 18 to 45 years with a viable fetus confirmed by ultrasound, microscopically confirmed uncomplicated malaria of any species with a parasitemia of ≥5/500 white blood cells, and no signs of labor. Patients with severe malaria, hyperparasitemia (≥4%), severe anemia (hematocrit < 20%), or known history of chronic diseases were excluded. After giving informed consent in their own language, pregnant women were randomized to take either AL+, ASMQ, or DP. The treatment allocation was concealed using sealed opaque envelopes. A computer-generated randomization of 1:1:1 in blocks of 15 was used. This RCT was open-label: only the readers of the ECG were blinded for the treatment allocation.

Drugs were given under full supervision for all doses. AL+ was given at a higher dose and for a longer period than the current standard: five tablets of Coartem (20/120 mg artemether/luemefantrine) were given twice a day for 4 days regardless of body weight, with 100 ml of chocolate milk each time. ASMQ was given once daily for 3 days as either a loose combination of artesunate (50 mg/tablet) plus mefloquine (250 mg/tablet) or a fixed-dose combination (artesunate/mefloquine, 100/220 mg) depending on availability. For the loose combination, the dose was rounded to the nearest quarter of a tablet for both drugs based on body weight (4 mg/kg artesunate and 8 mg/kg mefloquine). For the fixed-dose combination, two tablets were given each day to all women (with body weight >29 kg). DP was given based on body weight (2.4 mg/kg dihydroartemisinin and 20 mg/kg piperaquine) once daily for 3 days. Standard fixed-dose tablets containing 40/320 mg of dihydroartemisinin/piperaquine were used, and the dose was rounded up to the nearest half of a tablet. Recurrence of non-P. falciparum parasitemia during follow-up was treated with chloroquine (10 mg/kg on day 0 and 1 and 5 mg/kg on day 2) with the dose rounded to the nearest quarter of a tablet (one tablet contained 250 mg chloroquine phosphate).

After treatment, women were followed up weekly for clinical, obstetric, and parasitological assessment until delivery or for 63 days, whichever was later.

ECG assessment. A standard 12-lead ECG (Nihon Kohden ECG-1250K, Tokyo, Japan) was measured at baseline before drug administration (day 0), at 4 to 6 h following the last dose (defined as day peak), and on day 7 or after (day 7). ECG was assessed in a supine position after a short rest in the same position. ECGs were only assessed in around half the patients (259/511) enrolled in this study, depending on the availability of ECG machines at the study sites.

One assessor, who was blinded to the treatment allocation, read all ECG records manually. Another assessor independently read the ECGs of the first 180 patients. The end of the T wave was defined as the point of intersection between the isoelectric line and the tangent line to the steepest downslope of the T wave. If the U wave was fused with the T wave and its height was more than half of that of the T wave, the U wave was included for measurement of the QT (41). In total, six QRS complexes were measured using at least four different leads, and the median of these six complexes was taken (42). The minimum precision of reading was 0.5 mm, which corresponded to 10 ms at a speed of 50 mm/s. The heart rate given by the ECG machine was used to calculate the average RR interval (42). QRS interval was measured automatically by the machine or manually if the automatic reading was not provided. All concomitant medications used during the ECG assessment period were recorded.

Statistical analysis. Proportions of the study population with QT prolongation on day 0, day peak, and day 7 were summarized by treatment, using QTu, QTcF, QTcB, and QTcP (43). QT prolongation was defined either by the absolute value of >480 ms or >500 ms, or by the absolute increase of >30 ms or >60 ms from baseline (5, 44).

To compare the QT intervals with different heart rates, a correction method specifically for this study population (QTcP) was derived from a linear regression of log(QT) and log(RR) using the data on day 0 (45). Either QTcF, QTcB, or QTcP that was the least related to heart rate was used for further analyses. Linear mixed-effects models were used for the analyses. For interpretation, coefficients of linear regression were expressed as the predicted mean difference. Repeated measures analyses were conducted for QTc at different time points. The model assumed that there was no difference in the baseline QTc (46). Variable selection was done by backward elimination (47) using a P value of 0.05 by the Wald test as the cutoff. Variables that changed the predicted mean difference of treatment by more than 10% were kept in the multivariable model regardless of the P value if clinically considered a confounder (48). Symptoms that are known to be (or are potentially) associated with QT prolongation were assessed as covariates. Two-level random intercepts were used for within-person correlation (46).

The following three types of sensitivity analyses were conducted, including all variables in the final multivariable model: a model excluding episodes with any concomitant drugs known to be associated with QT prolongation (https://www.crediblemeds.org/) used, a model allowing the difference in QTc on
day 0 (46), and a model using the corrected JT interval, which is defined as QTc – QRS (49), as the outcome.

Stata/MP 16.1 (Stata Corp., TX, USA) was used for the statistical analyses.

Ethics. After the discussion with the Tak Province Border Community Ethics Advisory Board (T-CAB) (50), this study was approved by the Ethical Committee of the Faculty of Tropical Medicine, Mahidol University in Bangkok (TMEC 09-050) and the Oxford Tropical Research Ethics Committee (OXTREC 45-09). This study is registered in clinicaltrials.gov (NCT01054248).

Data availability. Data are available from MORU Tropical Health Network (https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing).

SUPPLEMENTAL MATERIAL

Supplemental material is available only online.

SUPPLEMENTAL FILE 1, PDF file, 0.9 MB.

ACKNOWLEDGMENTS

This study received partial financial support from the Holleypharm Pharmaceutical Company (Guangzhou, China). SMRU is part of the Wellcome Trust Mahidol University-Oxford Tropical Medicine Research Program funded by the Wellcome Trust of Great Britain. M.S. was supported by the University of Oxford Clarendon Fund.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

We would like to express our sincere thanks to the pregnant women, doctors, midwives, Say Bway Paw, and other medics, nurses, lab technicians, the teams of SMRU and MORU who made this work possible.

REFERENCES

1. White NJ. 2007. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 7:549–558. https://doi.org/10.1016/s1473-3099(07)70187-1.

2. White NJ, Loaareesuwan S, Warrell DA, Chongsuapjaisiddhi T, Bunnag D, Harinasuta T. 1981. Quinidine in falciparum malaria. Lancet 2:1069–1071. https://doi.org/10.1016/s0140-6736(81)91275-7.

3. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Chongsuapjaisiddhi T, White NJ, Kyle DE. 1993. Cardiac effects of antimalarial treatment with halofantrine. Lancet 341:1054–1056. https://doi.org/10.1016/s0140-6736(93)92412-m.

4. Bouchaud O, Imbert P, Touze JE, Doddoo AN, Danis M, Legros F. 2009. Fatal overdose. Elife 9:e58631. https://doi.org/10.7554/eLife.58631.

5. World Health Organization. 2017. The cardiotoxicity of antimalarials. WHO Evidence Review Group Meeting, Geneva, Switzerland, 13 to 14 October 2016. http://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-session2.pdf.

6. Haesler IL, Chau XHS, Guerin PJ, White NJ. 2018. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Med 16:200. https://doi.org/10.1186/s12916-018-1188-2.

7. Chau XHS, Win YN, Haesler IL, Tan JY, Loganganathan S, Saralamba S, Chan SKS, Ashley EA, Barnes KI, Baiden R, Bassi PU, Djimde A, Dorsey G, Duparc S, Hanboonkunupakam B, ter Kuile FO, Lacerda MVG, Nasa A, Nosten FH, Onyeji CO, Pukrittayakamee S, Siqueira AM, Tarning J, Taylor WR, Valentini G, van Vugt M, Weichselbaum DR, White NJ, Wu XJ. 2020. Factors affecting the electrocardiographic QT interval in malaria: a systematic review and meta-analysis of individual patient data. PLoS Med 17: e1003040. https://doi.org/10.1371/journal.pmed.1003040.

8. Watson JA, Tarning J, Hoglund RM, Baud FJ, Megarbane B, Clemenzy J-L, White NJ. 2020. Concentration-dependent mortality of chloroquine in overdose. Elife 9:e58631. https://doi.org/10.7554/eLife.58631.

9. Burger RJ, Visser BJ, Grobusch MP, van Vugt M. 2016. The influence of pregnancy on the pharmacokinetic properties of artemisinin combination therapy (ACT): a systematic review. Malar J 15:99. https://doi.org/10.1186/s12936-016-1160-6.

10. Costantini MM. 2014. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol 5:65. https://doi.org/10.3389/fphar.2014.00065.

11. Feghali M, Venkataramanan R, Caritis S. 2015. Pharmacokinetics of drugs in pregnancy. Semin Perinatol 39:512–519. https://doi.org/10.1053/j.sper.2015.08.003.

12. Drici MD, Clement N. 2001. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 24:575–585. https://doi.org/10.2165/00002018-200124080-00002.

13. Odening KE, Koenig G, Kirk M. 2016. Normalization of QT interval duration in a long QT syndrome patient during pregnancy and the postpartum period due to sex hormone effects on cardiac repolarization. HeartRhythm Case Rep 2:223–227. https://doi.org/10.1016/j.hrcr.2015.12.012.

14. Nosten F, Karbwang J, White NJ, Honeymoon Na Bangchang K, Bunnag D, Harinasuta T. 1990. Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. Br J Clin Pharmacol 30:79–85. https://doi.org/10.1111/j.1365-2125.1990.tb03746.x.

15. Nosten F, ter Kuile FO, Maelankiri L, Chongsuphajaisiddhi T, Nopdonrattakoon L, Tangkitchot S, Bunnag D, White NJ. 1994. Mefloquine prophylaxis prevents malaria during pregnancy; a double-blind, placebo-controlled study. J Infect Dis 169:595–603. https://doi.org/10.1093/infdis/169.3.595.

16. Benjamin JM, Moore BR, Salman S, Page-Sharp M, Tawat S, Yadi G, Lorry L, Siha PM, Batty KT, Robinson LJ, Mueller I, Davis TME. 2015. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and non-pregnant Papua New Guinean women. Antimicrob Agents Chemother 59:4260–4271. https://doi.org/10.1128/AAC.00326-15.

17. Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, Opika B, Owoch P, Ategeka J, Nkayirima J, Ochola J, Kihenda J, Kajubi R, Huang L, Jagannathan P, Muhindo M, Nakalembe M, Havlir D, Kamya MR, Dorsey G. 2016. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. N Engl J Med 374:928–939. https://doi.org/10.1056/NEJMoa1509150.

18. Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, Opika B, Owoch P, Ategeka J, Nkayirima J, Ochola J, Kihenda J, Kajubi R, Huang L, Jagannathan P, Muhindo M, Nakalembe M, Havlir D, Kamya MR, Dorsey G. 2016. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. N Engl J Med 374:928–939. https://doi.org/10.1056/NEJMoa1509150.

19. Kajubi R, Huang L, Jagannathan P, Chamankhah N, Were M, Riska VS, Kakuru A, Mwekaza N, Kamya M, Havlir D, Dorsey G. 2017. Antiretroviral therapy with efavirenz accentuates pregnancy-associated reduction of dihydroartemisinin-piperaquine exposure during malaria chemoprevention. Clin Pharmacol Ther 102:520–528. https://doi.org/10.1002/cpt.664.

20. Wallender E, Vucicevic K, Jagannathan P, Huang L, Natureeba P, Kakuru A, Muhindo M, Nakalembe M, Havlir D, Kamya M, Aweke F, Aweke FT. 2017. Antiretroviral therapy with efavirenz accentuates pregnancy-associated reduction of dihydroartemisinin-piperaquine exposure during malaria chemoprevention. Clin Pharmacol Ther 102:520–528. https://doi.org/10.1002/cpt.664.
20. Natureeba P, Kakuru A, Muhindo M, Ochieng T, Ategeka J, Koss CA, Plenty Saito et al. Antimicrobial Agents and Chemotherapy

April 2021 Volume 65 Issue 4 e02473-20 aac.asm.org 10